Quest Diagnostics (DGX) Receivables (2009 - 2026)

Quest Diagnostics has reported Receivables for 18 years, with the latest figure at $1.7 billion in Q2 2026.

• Quarterly Receivables rose 17.41% year-over-year to $1.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 17.41% YoY) and the FY2025 annual result came in at $1.4 billion, up 7.98% from the prior year.
• Receivables improved to $1.7 billion in Q2 2026 per DGX's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Receivables peaked at $1.7 billion in Q2 2026 and troughed at $1.2 billion in Q4 2022.
• A 5-year average of $1.4 billion and a median of $1.3 billion in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2026: Receivables dropped 16.9% in 2022, then advanced 17.41% in 2026.
• Over 5 years, Receivables stood at $1.2 billion in 2022, then gained by 1.26% to $1.2 billion in 2023, then rose by 7.77% to $1.3 billion in 2024, then climbed by 7.98% to $1.4 billion in 2025, then climbed by 18.32% to $1.7 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $1.7 billion, $1.6 billion, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.